Also, Sen. Herb Kohl (D-WI) wants the U.S. Federal Trade Commission to examine the impact that consolidation in the pharmaceutical industry may be having on the nation's drug supply.
In its Tuesday report, Premier issued several recommendations with a warning to hospitals, doctors and pharmacists to avoid buying from such grey market companies.
"Understand[ing]...the possibility that supplied drugs may be counterfeit, stolen, diverted, mishandled and/or adulterated," is the first of Premier's eight recommendations to healthcare purchasers to avoid getting caught by this practice," Premier admonished in its report.
The purchasing alliance said health system purchasers should develop a policy guiding which distributors and suppliers they will do business with, and document specific reasons for any exceptions.
Premier issued the following additional recommendations:
"Our suggestion is to stay out of these markets," said Alkire.
A hearing has been scheduled Sept. 21 before the U.S. Food and Drug Administration.
Drug Shortages Increasing at 'Alarming Rate,' Says AHA
Senator Urges FTC to Examine Link Between Drug Shortages, Pharma Consolidation
Oncology Drug Shortage Rising
Drug Shortages Raise Costs, Put Patients at Risk